(A) The effect of FMD on breast tumor growth (4T1) in immunodeficient BALB/c nude mice (n = 15) (see Figure S4 A–S4E).

(B) The survival of wild-type (WT) and nude mice injected with high doses of DXR and undergoing the ad libitum or FMD regimens.

(C–H) 4T1 breast tumor-bearing mice were treated with DXR, FMD + DXR alone or in combination with αCD8 monoclonal antibody and (C–E) circulating levels of (C, E) CD3+/CD8+ and (D, E) CD3+/CD4+/CD25+ were determined by FACS (n = 7).

(F) Tumor volumes of FMD + DXR and FMD + DXR + αCD8 were measured at multiple time points.

(G) TILs were also assessed in tumor samples collected from the same animals.

(H) Circulating lymphocytes from DXR, FMD + DXR, DXR + αCD8, and FMD + DXR + αCD8. These animals were collected and cultured ex vivo with 4T1 cells for 24 hr and viability was assessed by MTT reduction.

(I) Mice were immunized by subcutaneous inoculation (in the left flank) with 4T1 breast cancer cells pre-conditioned in vitro with either ad libitum (2 g/l glucose + 10% FBS) or STS medium (0.5 g/l glucose + 1% FBS) with or without DXR (5 μM). 7 days after the immunization, the same animals were inoculated with naive 4T1 cells in the right flank (n = 10).

(J and K) Tumor progression for the immunization (left) and the naive (right) sides are reported.